AR010122A1 - Procedimiento de recuperacion de vwf altamente purificado o complejo de factor viii/vwf altamente purificado - Google Patents
Procedimiento de recuperacion de vwf altamente purificado o complejo de factor viii/vwf altamente purificadoInfo
- Publication number
- AR010122A1 AR010122A1 ARP980100836A ARP980100836A AR010122A1 AR 010122 A1 AR010122 A1 AR 010122A1 AR P980100836 A ARP980100836 A AR P980100836A AR P980100836 A ARP980100836 A AR P980100836A AR 010122 A1 AR010122 A1 AR 010122A1
- Authority
- AR
- Argentina
- Prior art keywords
- presented
- applicant
- vwf
- diskette
- highly purified
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 238000011084 recovery Methods 0.000 title abstract 2
- 108010054218 Factor VIII Proteins 0.000 abstract 2
- 102000001690 Factor VIII Human genes 0.000 abstract 2
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 1
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/824—Immunological separation techniques
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/108331—Preservative, buffer, anticoagulant or diluent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2525—Stabilizing or preserving
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describe un procedimiento de recuperacion de vWF altamente purificado o factor VIII/vWF altamente purificado mediante cromatografía de inmunoafinidad, qcaracteriza porque vWF o complejo de factor VIII/ vWF ligado a un inmunoadsorbeneluidomediante un agente eluyente que contiene como ingrediente activo esencialanfotero, mientras retiene la integridad molecular del vWF o del complejo de facAdemás, la invencion se refiere a una composicion que contiene vWF altamente puruna actividadespecífica de al menos 100 U/mg de proteína, obtenible por cromatoinmunoafinidad, así como al uso de esta composicion para producir un medicamentotratamiento de vWD o de hemofilia A fenotípica. DATOS DEL DISQUETTEPRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTE DATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTE DATOS DELDISQUETTE PRESENT ADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTE DATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTE DATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTE DATOS DEL D ISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTE DATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0033997A AT406867B (de) | 1997-02-27 | 1997-02-27 | Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR010122A1 true AR010122A1 (es) | 2000-05-17 |
Family
ID=3487975
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980100834A AR010120A1 (es) | 1997-02-27 | 1998-02-25 | PROCEDIMIENTO DE RECUPERACIoN DE vWF, COMPOSICION QUE CONTIENE vWF PURIFICADO, Y USO DE LA MISMA |
| ARP980100836A AR010122A1 (es) | 1997-02-27 | 1998-02-25 | Procedimiento de recuperacion de vwf altamente purificado o complejo de factor viii/vwf altamente purificado |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980100834A AR010120A1 (es) | 1997-02-27 | 1998-02-25 | PROCEDIMIENTO DE RECUPERACIoN DE vWF, COMPOSICION QUE CONTIENE vWF PURIFICADO, Y USO DE LA MISMA |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6579723B1 (es) |
| EP (1) | EP1012191B1 (es) |
| JP (1) | JP4250769B2 (es) |
| AR (2) | AR010120A1 (es) |
| AT (2) | AT406867B (es) |
| AU (1) | AU734277B2 (es) |
| CA (1) | CA2282842C (es) |
| DE (1) | DE59813968D1 (es) |
| DK (1) | DK1012191T3 (es) |
| ES (1) | ES2285758T3 (es) |
| NO (1) | NO323861B1 (es) |
| SI (1) | SI1012191T1 (es) |
| WO (1) | WO1998038218A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6926894B2 (en) * | 2000-11-22 | 2005-08-09 | Baxter Aktiengesellschaft | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
| JP3862613B2 (ja) | 2002-06-05 | 2006-12-27 | キヤノン株式会社 | 画像処理装置及び画像処理方法並びにコンピュータプログラム |
| DE10246125A1 (de) * | 2002-10-01 | 2004-04-15 | Aventis Behring Gmbh | Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren |
| FR2874216B1 (fr) | 2004-08-16 | 2006-11-03 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu |
| EP1789096A4 (en) | 2004-09-07 | 2009-07-08 | Archemix Corp | APTAMERS FOR THE VON WILLEBRAND FACTOR AND ITS USE AS THERAPEUTICS FOR THROMBOTIC DISEASES |
| US7566701B2 (en) * | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
| US20070066551A1 (en) * | 2004-09-07 | 2007-03-22 | Keefe Anthony D | Aptamer medicinal chemistry |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| WO2008150495A2 (en) * | 2007-06-01 | 2008-12-11 | Archemix Corp. | Vwf aptamer formulations and methods for use |
| FR2920429B1 (fr) * | 2007-08-30 | 2012-10-05 | Lfb Biotechnologies | Procede de purification du facteur viii et du facteur von willebrand |
| US11197916B2 (en) * | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| AU2008345218B2 (en) * | 2007-12-28 | 2015-02-19 | Takeda Pharmaceutical Company Limited | Counter-pressure filtration of proteins |
| IT1396528B1 (it) | 2009-01-19 | 2012-12-14 | Kedrion Spa | Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn). |
| PT2499165T (pt) | 2009-11-13 | 2016-10-28 | Grifols Therapeutics Inc | Preparações que contêm o fator de von willebrand (vwf), e métodos, kits e utilizações relacionadas com as mesmas |
| SG191186A1 (en) | 2010-12-15 | 2013-07-31 | Baxter Int | Eluate collection using conductivity gradient |
| JP6236948B2 (ja) * | 2013-07-17 | 2017-11-29 | 東ソー株式会社 | 抗体精製用溶出液および当該溶出液を用いた抗体精製方法 |
| EP3205665A1 (en) * | 2016-02-11 | 2017-08-16 | Octapharma AG | Method of separating factor viii from blood products |
| JP2021519280A (ja) | 2018-03-21 | 2021-08-10 | バクスアルタ インコーポレイテッド | クロマトグラフィー法によるｖｗｆとｖｗｆプロペプチドの分離 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1982004395A1 (en) | 1981-06-18 | 1982-12-23 | Erik Gustaf Birger Blombaeck | A process in purification and concentration of the factor viii complex |
| US4361509A (en) * | 1981-12-14 | 1982-11-30 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| FR2570276B1 (fr) * | 1984-09-18 | 1987-09-04 | Immunotech Sa | Procede d'obtention du complexe fviii/vwf a usage therapeutique et produits en resultant |
| US5200510A (en) | 1987-06-16 | 1993-04-06 | Zymogenetics, Inc. | Method for purifying factor viii:c, von willebrand factor and complexes thereof |
| US4774323A (en) * | 1987-06-29 | 1988-09-27 | Rorer Pharmaceutical Corporation | Purification of von Willebrand Factor solutions using gel permeation chromatography |
| US5006642A (en) * | 1987-06-29 | 1991-04-09 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Purification of von Willebrand Factor by affinity chromatography |
| DE3904354A1 (de) | 1989-02-14 | 1990-08-16 | Behringwerke Ag | Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung |
| FR2665449B1 (fr) | 1990-08-02 | 1995-04-14 | Aquitaine Developp Transf Sang | Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant. |
| FR2662166A1 (fr) * | 1990-05-18 | 1991-11-22 | Fondation Nale Transfusion San | Procede de preparation de facteur viii de tres haute purete comprenant une etape rapide d'immunoadsorption. |
| AU670793B2 (en) | 1992-04-30 | 1996-08-01 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor VIII complex |
| IT1256622B (it) | 1992-12-04 | 1995-12-12 | Sclavo Spa | Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale. |
| DE4435392B4 (de) | 1994-10-04 | 2008-02-07 | Immuno Ag | Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| AT403764B (de) | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| AT403765B (de) * | 1996-04-12 | 1998-05-25 | Immuno Ag | Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex |
| CA2251558C (en) | 1996-04-12 | 2005-11-22 | Immuno Aktiengesellschaft | Highly purified factor viii complex |
-
1997
- 1997-02-27 AT AT0033997A patent/AT406867B/de not_active IP Right Cessation
-
1998
- 1998-02-18 AU AU61998/98A patent/AU734277B2/en not_active Expired
- 1998-02-18 EP EP98903938A patent/EP1012191B1/de not_active Expired - Lifetime
- 1998-02-18 DK DK98903938T patent/DK1012191T3/da active
- 1998-02-18 CA CA002282842A patent/CA2282842C/en not_active Expired - Lifetime
- 1998-02-18 SI SI9830884T patent/SI1012191T1/sl unknown
- 1998-02-18 AT AT98903938T patent/ATE359302T1/de active
- 1998-02-18 WO PCT/AT1998/000033 patent/WO1998038218A1/de active IP Right Grant
- 1998-02-18 ES ES98903938T patent/ES2285758T3/es not_active Expired - Lifetime
- 1998-02-18 US US09/367,362 patent/US6579723B1/en not_active Expired - Lifetime
- 1998-02-18 JP JP53705598A patent/JP4250769B2/ja not_active Expired - Lifetime
- 1998-02-18 DE DE59813968T patent/DE59813968D1/de not_active Expired - Lifetime
- 1998-02-25 AR ARP980100834A patent/AR010120A1/es not_active Application Discontinuation
- 1998-02-25 AR ARP980100836A patent/AR010122A1/es active IP Right Grant
-
1999
- 1999-08-24 NO NO19994084A patent/NO323861B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AT406867B (de) | 2000-10-25 |
| SI1012191T1 (sl) | 2007-08-31 |
| NO994084D0 (no) | 1999-08-24 |
| US6579723B1 (en) | 2003-06-17 |
| NO994084L (no) | 1999-10-19 |
| CA2282842A1 (en) | 1998-09-03 |
| DE59813968D1 (de) | 2007-05-24 |
| AU734277B2 (en) | 2001-06-07 |
| DK1012191T3 (da) | 2007-08-06 |
| AU6199898A (en) | 1998-09-18 |
| AR010120A1 (es) | 2000-05-17 |
| JP4250769B2 (ja) | 2009-04-08 |
| CA2282842C (en) | 2010-02-02 |
| EP1012191B1 (de) | 2007-04-11 |
| ATA33997A (de) | 2000-02-15 |
| JP2001513762A (ja) | 2001-09-04 |
| ES2285758T3 (es) | 2007-11-16 |
| NO323861B1 (no) | 2007-07-16 |
| ATE359302T1 (de) | 2007-05-15 |
| WO1998038218A1 (de) | 1998-09-03 |
| EP1012191A1 (de) | 2000-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR010122A1 (es) | Procedimiento de recuperacion de vwf altamente purificado o complejo de factor viii/vwf altamente purificado | |
| DK0740650T3 (da) | Codrugs som metode til styret transport af lægemiddel | |
| ES2173978T3 (es) | Utilizacion de un alcohol graso insaturado. | |
| CO4560552A1 (es) | Antagonistas de receptores de taquicininas no peptidicos | |
| AR027391A1 (es) | Composiciones farmaceuticas de toxina botulinica | |
| ES2159591T3 (es) | Composicion de liberacion controlada. | |
| UY28213A1 (es) | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. | |
| BRPI0407001A (pt) | Método para aumentar a estabilidade de uma proteìna purificada, uso de uma proteìna ligante sìtio-especìfica ativa, método para aumentar a produção de uma proteìna recombinante e composição farmacêutica | |
| BRPI0414907A (pt) | formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas | |
| BR0316050A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
| CO4340618A1 (es) | Composicion farmaceutica para liberacion controlada | |
| BRPI9917007B8 (pt) | azabicicloalcanos como moduladores de ccr5, composição farmacêutica contendo os mesmos, bem como seu uso | |
| AR019690A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas sustancias activas | |
| DE69003611D1 (de) | Abgabesysteme fuer quaternaere und verwandte verbindungen. | |
| ES2081531T3 (es) | Composiciones farmaceuticas que contienen rifaximina para el tratamiento de infecciones vaginales. | |
| ES2193159T3 (es) | Una formulacion de factor de coagulacion viii. | |
| BR9914251A (pt) | Formulações orais de liberação sustentada | |
| AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
| ES2156603T3 (es) | Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina. | |
| GT199700009AA (es) | Terapia combinada para la osteoporosis | |
| BR9910336A (pt) | Composição farmacêutica compreendendo composto de macrolìdeo | |
| BR9506847A (pt) | Composto composição farmacêutica uso de um composto processo para o tratamento da dor | |
| AR039511A1 (es) | Agentes que regulan, inhiben, o modulan la actividad y/o la expresion del factor de crecimiento del tejido conjuntivo (ctgf) como unico medio para disminuir la presion intraocular y para tratar las retinopatias glaucomatosas/neuropatias opticas | |
| CL2008003938A1 (es) | Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |